Spark Therapeutics, Inc.
SPARK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SPARK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2019.
Tracking 1 pipeline candidate · 19 clinical trials for Spark Therapeutics, Inc..
Run Spark Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Spark Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
71.9 months
D/E 1.03
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Spark Therapeutics, Inc.'s lead drug candidate?
Spark Therapeutics, Inc.'s most advanced tracked candidate is luxturna (Approved) for biallelic RPE65 mutation-associated retinal dystrophy.
Who is the CEO of Spark Therapeutics, Inc.?
Jeffrey D. Marrazzo is the chief executive officer of Spark Therapeutics, Inc. (SPARK).
What therapeutic areas does Spark Therapeutics, Inc. focus on?
Spark Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Ophthalmology, Respiratory, Dermatology, Hematology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.